Literature DB >> 11972977

Preparation and characterisation of attenuated cold-adapted influenza A reassortants derived from the A/Leningrad/134/17/57 donor strain.

M D Wareing1, G A Marsh, G A Tannock.   

Abstract

The development of a rapid cell culture method for the preparation of cold-adapted (ca) influenza A reassortant viruses is described and compared with a currently used egg method. Mixtures of the ca donor A/Leningrad/134/17/57-ca (A/Len/17) and A/Beijing/32/92 (A/Beij/32), a recent H3N2 epidemic strain, were used to co-infect chicken embryo kidney (CEK) cell cultures; reassortant progeny were selected using an infectious centre assay. The assay was capable of detecting interference where the infectivity ratio for A/Len/17 and A/Beij/32 was 1:7. Progeny viruses were characterised genetically by amplification of defined regions within each of the six internal genes by PCR and identification of the products by restriction enzyme analysis. Reassortants were also tested for ca and temperature-sensitive (ts) phenotype and the identity of the surface antigens. The infectious centre assay was shown to be an effective method for isolating reassortant progeny that possessed the haemagglutinin and neuraminidase surface antigens of A/Beij/32. Reassortants with the six internal genes derived from the donor strain and possessing the ca and ts phenotype were readily obtained when (a) an infectivity ratio of 1:49 was used and (b) two plaque-to-plaque isolations of progeny virus were made after growth at 25 degrees C and one at 34 degrees C, both in the presence of antiserum to the donor strain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972977     DOI: 10.1016/s0264-410x(02)00056-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production.

Authors:  Svetlana Shcherbik; Sheila B Sergent; William G Davis; Bo Shu; John Barnes; Irina Kiseleva; Natalie Larionova; Alexander Klimov; Tatiana Bousse
Journal:  J Virol Methods       Date:  2013-09-18       Impact factor: 2.014

Review 2.  Current Opinion in LAIV: A Matter of Parent Virus Choice.

Authors:  Irina Kiseleva
Journal:  Int J Mol Sci       Date:  2022-06-19       Impact factor: 6.208

3.  Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiency.

Authors:  Irina Kiseleva; Natalie Larionova; Ekaterina Fedorova; Ekaterina Bazhenova; Irina Dubrovina; Irina Isakova-Sivak; Larisa Rudenko
Journal:  Open Microbiol J       Date:  2014-07-11

4.  Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models.

Authors:  Andrey Rekstin; Yulia Desheva; Irina Kiseleva; Ted Ross; David Swayne; Larisa Rudenko
Journal:  Open Microbiol J       Date:  2014-12-31

Review 5.  Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza.

Authors:  Irina Kiseleva; Natalie Larionova; Larisa Rudenko
Journal:  Open Microbiol J       Date:  2017-11-30

6.  New Points of Departure for More Global Influenza Vaccine Use.

Authors:  Irina Kiseleva
Journal:  Vaccines (Basel)       Date:  2020-07-23

7.  Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.

Authors:  Svetlana Shcherbik; Nicholas Pearce; Amanda Balish; Joyce Jones; Sharmi Thor; Charles Todd Davis; Melissa Pearce; Terrence Tumpey; David Cureton; Li-Mei Chen; Julie Villanueva; Tatiana L Bousse
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

8.  Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.

Authors:  Svetlana V Shcherbik; Nicholas C Pearce; Marnie L Levine; Alexander I Klimov; Julie M Villanueva; Tatiana L Bousse
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

9.  Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.

Authors:  Yulia Desheva; Ivan Sychev; Tatiana Smolonogina; Andrey Rekstin; Natalia Ilyushina; Vladimir Lugovtsev; Anastasia Samsonova; Aleksey Go; Anna Lerner
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240

10.  Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets.

Authors:  Larisa Rudenko; Irina Kiseleva; Elena Krutikova; Ekaterina Stepanova; Irina Isakova-Sivak; Svetlana Donina; Andrey Rekstin; Maria Pisareva; Ekaterina Bazhenova; Tatiana Kotomina; Anastasia Katelnikova; Arman Muzhikyan; Valery Makarov; Erin Grace Sparrow; Guido Torelli
Journal:  Vaccines (Basel)       Date:  2018-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.